Allogene Therapeutics
Elizabeth C. has extensive experience in the fields of biotechnology and engineering, currently serving as a Scientist at Allogene Therapeutics since March 2019, with prior roles as Senior Associate Scientist and Associate Scientist. Elizabeth began in the industry as an R&D Intern at Lonza from July 2017 to March 2018, contributing to the development of an allogenic bioreactor platform and conducting various tests in compliance with regulatory standards. Previous research experience includes work as an Undergraduate Researcher at The Johns Hopkins University's Michael J. Betenbaugh Laboratory, focusing on algae lipid production and growth conditions, and mentoring high school students during a summer research program. Elizabeth holds a Master of Science in Engineering in Chemical and Biomolecular Engineering from The Johns Hopkins University, where education was completed from 2017 to 2018, following a Bachelor's degree from the same institution from 2013 to 2017.
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.